Using PET with the radiolabeled amino acid F-18 fluoroethyl-tyrosine (F-18-FET) can significantly help determine the efficacy of radiotherapy in certain cancer patients who develop brain metastases, according to a study in the Journal of Nuclear Medicine.
The medical device company NeuroOne Medical Technologies Corporation's new thin-film electrode technology, Evo Cortical, offers a potentially faster and less invasive diagnostic tool for identifying brain abnormalities in patients with epilepsy and brain tumors.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
McMaster University researchers have identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, the most serious form of pediatric brain cancer, making these aggressive forms of the disease more susceptible to therapy.
Brain cancer in children is always a devastating diagnosis, but McMaster University researchers may have found a way to have the most serious types of pediatric brain cancer respond better to therapies.
Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies. The work also found the Wnt pathway, which has historically been considered cancer-promoting, to function as a cancer inhibitor in certain contexts.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
A new and sophisticated twist on the technology that brings us images of a fetus in utero will soon be used by physicians at Miami Neuroscience Institute and Miami Cancer Institute to treat some patients with movement disorders and brain tumors.
Glioblastomas are among the most aggressive brain tumors in adults and difficult to treat due to their rapid growth and their diversity. Usually, the malignant tumors cannot be completely or permanently removed by surgery. Thus, a combined radio- and chemotherapy follows, which, however, can be associated with side effects on the entire human body.
Radiotherapy changes the behavior of immune cells. In a study on mice, researchers were able to reprogram them to improve the effectiveness of treatment and, consequently, the survival rate.
A neurosurgeon at North Shore University Hospital has performed first-of-its-kind brain tumor surgery on Long Island using Synaptive’s Modus V™ 3D exoscope. The innovative technology is a fully automated, robotic digital microscope that combines advanced optics with 3D visualization, video processing and robotic automation allowing for a more precise excision of brain tumors.
In a study funded by the National Institutes of Health, researchers showed that experimental drugs designed to lower the body’s natural production of alpha-ketoglutarate extended the lives of mice harboring DIPG tumors by slowing the growth of the cancer cells. Interestingly, they also found that artificially raising alpha-ketoglutarate levels with DIPG-causing genes may slow the growth of other brain tumors
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma. A McGill-led study published in Nature Communications reveals that suppressing the OSMR gene can improve the effectiveness of radiation therapy.
In the operating rooms at Southern New Hampshire Medical Center, surgeons have long offered robotic-assisted surgery using the da Vinci surgical system. The system is used for robotic-assisted minimally invasive procedures by cardiologists, colorectal surgeons, general surgeons, gynecological surgeons, head and neck surgeons, thoracic surgeons, and urologic surgeons. The existing system in Nashua is set to be upgraded, meaning patients will experience the most accurate, safe and successful robotic-assisted surgery available.
Findings, which appear in the journal Cancer Cell, suggest that simultaneously targeting two energy-production pathways within the cancer cells could help overcome the effects of a cancer-causing mutation that is one of the hallmarks of DIPG, or diffuse intrinsic pontine glioma, and similar tumors.
Specific genomic biomarkers can be used to identify glioma patients most likely to benefit from post-radiation chemotherapy and serve as a significant predictor of overall and progression-free survival, according to new data published by researchers at The Ohio State University Comprehensive Cancer Center.
Brain tumors are typically diagnosed using MRI imaging because taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient’s poor health conditions. Researchers at Washington University in St. Louis are developing a method to diagnose brain tumors without any incisions.
An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s.
Much like the GPS technology that we use in cars and travelling, Neuro-navigation is a state-of-the-art technology that helps surgeons in a similar way to direct and guide them to the exact location of the tumor during surgery without causing any harm to the surrounding areas. This is achieved by feeding the patient’s preoperative Brain MRI or CT scan data into the software which are used as coordinates intraoperatively.
Glioblastoma, the most widespread and lethal primary brain tumor in adults, is notoriously difficult to treat due to the surrounding lack of oxygen essential to the effectiveness of current treatment. A team of CNRS and University of Caen Normandie researchers have successfully delivered the necessary oxygen to the tumor using zeolite nanocrystals.
A mouse model of glioblastoma suggests that this recalcitrant cancer originates from a pool of stem cells that can be a significant distance away from the resulting tumors. The findings of a new study, led by Children's National Hospital researchers and published July 22 in the journal Nature Communications, suggest new ways to fight this deadly disease.
Researchers affiliated with the University of Sao Paulo's Ribeirao Preto Medical School (FMRP-USP) in Brazil have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children.
After discovering how a specific gene fuels a deadly form of children's brain tumor, University of Manitoba researchers have successfully decreased this cancer in mice.
Scientists at the University of Virginia School of Medicine have made a new discovery that could make all the difference in diagnosing the deadliest type of brain tumor. They’ve identified a gene that causes the deadliest brain tumor: glioblastoma.
The recently published study used cutting-edge methods, such as single cell sequencing, to conduct genome-wide analysis of individual tumor cells and to describe their molecular biological characteristics. The group found that ependymomas are very heterogeneous and consist of many cells with different characteristics, which complicates their treatment and might be the reason for chemotherapy resistance.
Working at the Australian Synchrotron facility in Melbourne, the scientists tested a technique for the treatment of high-grade brain cancer using personalized microbeam radiation therapy (MRT), combining it with an innovative assessment of tumor dose-coverage. MRT uses ultra-fine X-rays—each smaller in diameter than a human hair—to destroying the cancerous tissue while not harming the surrounding healthy tissue.
A Purdue University cancer innovator and his team have developed a promising new approach to treating these tumors using a type of immune cell called the natural killer (NK) cell. The team genetically modifies the NK cells to more specifically target and kill cancer cells.
As an ever-increasing number of complex surgeries are regularly being performed in an outpatient setting at ambulatory surgical centers, some brain tumor resections may be safe and feasible for appropriately selected patients, new research suggests.
Severance Hospital said it and two other institutions have jointly developed a biomarker and treatment for predicting the prognosis of glioblastoma, incurable cancer.
New findings suggest that maintaining high PAR levels (and low NAD+ levels), in combination with chemotherapy, may uniquely target IDH mutant glioma cells. Considering this, Hiroaki Nagashima, MD, PhD, research fellow and lead author, devised a new treatment strategy and tested it in tumor cells and animal models.
Gliomas with mutations in what are called the isocitrate dehydrogenase (IDH) genes are the most common brain tumors diagnosed in younger adults aged 18 to 45 years. Patients can benefit from aggressive surgery, along with radiation and chemotherapy treatments, but these therapies are not curative in many cases.
In a study published in eLife, researchers described the development of the Risk Assessment Population IDentification (RAPID) tool, an open-source machine learning algorithm. The tool revealed coordinated patterns of protein expression and modification associated with survival outcomes.
Israeli researchers have succeeded in destroying breast cancer cells after developing a new treatment that "combines the application of low-frequency ultrasound and microbubbles," Tel Aviv University's Department of Biomedical Engineering announced on Thursday. "Once the ultrasound is activated, the microbubbles attach themselves to cancer cells and explode like intelligent, targeted missiles, creating holes in the cell membrane and thus allowing the drug to be delivered."
Researchers at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) developed LIH383, a novel molecule that binds to and blocks a previously unknown opioid receptor in the brain, thereby modulating the levels of opioid peptides produced in the central nervous system (CNS) and potentiating their natural painkilling and antidepressant properties.
A noninvasive way to make a diagnosis of brain cancer would be a game-changer for both patients and healthcare practitioners, since access tumor tissue is not always possible. Another challenge in treating brain cancers is the accurate diagnosis of subtypes of brain cancers, information that is used to determine prognosis and assist in treatment planning.
A new blood test is promising a non-invasive way for clinicians to diagnose and classify brain tumors. The test will need further verification before it reaches clinical practice but it points to a novel way for doctors to detect brain cancer without the need for surgical tissue biopsies.
The University of Virginia School of Medicine is pioneering the use of focused ultrasound to kill cells associated with glioblastoma, a deadly brain tumor.T he technique uses a sonosensitizing drug to sensitize cancer cells to sound waves. The cancer cells are then hit with a focused ultrasound, which creates tiny bubbles inside the cancer cells to make them die.
Local researchers said they have developed a new nanotherapy that targets and treats a brain tumor. A joint research team of Professor Kim Do-kyoung at Kyung Hee University College of Medicine and Professor Kim Hyo-young at the Korea Institute of Science and Technology said on Thursday the novel nanotherapy could target glioblastoma, the most common brain cancer.
Researchers at Uppsala University have performed whole-genome sequencing to identify functional mutations and their effect on genes relevant to the development of glioblastoma (GBM).
Artificial Intelligence (AI) has enabled in pushing the boundaries of medical research. Proving that AI can help in better diagnosis and treatment of brain tumors, scientists have developed a new machine-learning algorithm that can classify tumors based on the severity.
Researchers from the Universities of Toronto and McMaster have just achieved promising results in trials of a new treatment for glioblastoma, a widespread and aggressive form of brain cancer.
One of our key tasks was to identify functional mutations associated with regulatory elements and potential relevance to the development of cancer cells, and to distinguish them from all random variations without presumed significance.
Endoscopic brain tumor surgery is minimally invasive treatment procedure that allows neurosurgeons to find and treat the conditions that are deep within the brain or access them through the nose. During this surgical method, thin tubing that transmits the video images of the brain is inserted through one or two small incisions in the skull or through an opening in the body.
NorthShore University HealthSystem (NorthShore) neurosurgeon, Julian Bailes, MD, is the first in Illinois to begin offering GammaTile® Therapy, a new approach to treating malignant brain tumors. The FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) is designed to delay tumor regrowth for patients with high grade gliomas, meningiomas and brain metastases.
Northwest Biotherapeutics, Inc. (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.
Oncologists hoping for more precise and individualized care for patients with brain cancers and metastases are continuing to research liquid biopsy technologies that could help them more easily and consistently analyze tumor genomics and monitor patients in ways that have so far been either difficult or impossible.
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin. The study captures in granular detail how the functions, locations and characteristics of various immune cells sculpt the tumor microenvironment (TME) to thwart immune attack, support cancer cell survival and drive tumor progression.
A team of researchers at the University of Zurich (UZH) and the University Hospital Zurich (USZ) has now found what types of immune cells are present in what numbers in different types of brain tumors. These very precise "tumor maps" are essential to gain a better understanding of the individual immune components in the tumor and to develop targeted immunotherapies that activate an immune defense reaction.
The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a new Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
GBM is an aggressive form of cancer in the brain that is typically fatal. But new findings by VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.
"LITT stands for laser interstitial thermal therapy," says Dr. Scott Shepard, a neurosurgeon at Temple Health. The procedure uses a laser inserted into the brain through a tiny, pencil-sized hole to heat lesions or abnormalities.
Combining immunotherapy with tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice, according to new research out of Sanford Burnham Prebys.
Scientists at Sanford Burnham Prebys say they have discovered that combining immunotherapy with tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The findings also hold implications for other cancers that do not respond to immunotherapy.
Intel Labs and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) are co-developing a technology to enable a federation of 29 international healthcare and research institutions led by Penn Medicine to train artificial intelligence (AI) models that identify brain tumours using a privacy-preserving technique called federated learning.
Radiation is a key component of the standard-of-care treatment for the deadly brain cancer, glioblastoma; however, the treatment is rarely curative. While the growth of glioblastoma cells is often stalled by radiation, tumor growth inevitably resumes in nearly all treated patients.
project that will ultimately involve more than 15,000 patients in a first-time attempt to build a consensus model and help inform clinical decisions, Stat reports.
Research in cancer therapy is putting a lot of effort not only in the development of new drugs, but also in proposing new targeting strategies to selectively treat cancer cells. This would limit the dose of administered drugs as much as possible, decreasing the undesirable effects of chemotherapy, and, at the same time, increasing the efficacy of the treatment.
University of Virginia researchers are pioneering the use of focused ultrasound to defy the brain's protective barrier so that doctors could, at last, deliver many treatments directly into the brain to battle neurological diseases.
The approach, the researchers hope, could revolutionize treatment for conditions from Alzheimer's to epilepsy to brain tumors - and even help repair the devastating damage caused by stroke.
Focused ultrasound, the researchers hope, could revolutionize treatment for conditions from Alzheimer's to epilepsy to brain tumors -- and even help repair the devastating damage caused by stroke.
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has discovered that adding a drug more commonly used for schizophrenia alongside a radiation treatment helps to better treat glioblastoma, one of the deadliest and more aggressive brain tumors to treat.
Neurons and immune cells work together to promote tumor growth in neurofibromatosis type 1, research in mice suggests
The treatment, developed by TVAX Biomedical Inc., uses immunotherapy to treat glioblastoma, a type of malignant brain tumor. TVAX received a fast-track designation from the Food and Drug Administration, which allows the company to accelerate the approval process for the treatment and communicate more frequently with the FDA.
Promising new treatments for both primary and metastatic brain tumors, including gene therapy approaches, are constantly under development; however, brain neoplasms present tremendous challenges to effective therapeutic delivery.
A novel approach to treat medulloblastoma and ependymoma, researchers were able to deliver appropriately targeted chimeric antigen receptor (CAR) T cell therapy directly into the cerebrospinal fluid that surrounds the tumor.
The researchers report in the journal Nature Medicine that this approach was effective in treating these cancers in mouse models of human disease. The findings support further clinical studies to evaluate this strategy to treat pediatric brain cancers, the most common cause of cancer death in childhood.
Artificial intelligence may reduce the need for glioma brain cancer patients to have biopsies to determine the best treatment for their tumors, researchers report.
Currently, it's common to remove glioma samples from patients and analyze them to select appropriate therapy.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors.
Cancers whose cells are riddled with large numbers of DNA mutations often respond favorably to drugs called checkpoint blockers that unleash the immune system against the tumor. But a new study shows that malignant brain tumors known as gliomas generally don’t respond to the immunotherapy drugs.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors. The researchers found when the drug was given to mice 24 hours after the animals were exposed to a dose of radiation, it completely prevented cognitive decline from occurring, and that it did not reduce the efficacy of the radiation treatment.
The first sign of trouble for a patient with a growing brain tumor is often a seizure. Such seizures have long been considered a side effect of the tumor. But now a joint team of Columbia engineers and cancer researchers studying brain tumors has found evidence that the seizures caused by an enlarging tumor could spur its deadly progression.
Brain cancer in infants can be successful treated with targeted drugs, according to the findings published in Cancer Discovery. Babies and very young children, diagnosed when they are less than 12 months old, tend to have a better outcome – with around two thirds surviving five years or more.
The joint research team of Seoul National University Hospital (SNUH) and Massachusetts General Hospital (MGH) attached to Harvard University College of Medicine has recently released the results of analyzing the genetic mutations of metastatic brain tumors and primary lung cancer.
A team of researchers for Yale School of Medicine and Beijing Normal University just published a breakthrough study detailing a new method that offers a promise at treatment. The solution? Nanoparticles.
A group of researchers has devised a new way to study this rapidly spreading cancer, using a three-dimensional structure made of an agglomeration of human brain cells and biomaterials. Their work could help medical professionals better understand how the tumor grows and to speed up the potential discovery of new drugs to fight it.
Diverse Biotech, Inc. has announced it has signed an initial partnership agreement with The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center to study its potential new therapeutic candidates in glioblastoma. The research will be performed in animal models of the disease to evaluate the efficacy and tissue distribution of Diverse Biotech's new drug compounds.
To help doctors differentiate between the severity of cancers in the brain, an international team of researchers built a machine learning model that uses complex mathematics to learn how various types of brain tumors look in the brain.
In a recent study published in Autophagy, researchers at Kanazawa University show how abnormalities in a gene called TPR can lead to pediatric brain cancer.
The combined analysis of texture parameters of the CARS and TPEF signal proved to be most suited for the discrimination of non-tumor brain versus brain tumors (low and high grade astrocytoma, oligodendroglioma, glioblastoma, recurrent glioblastoma, brain metastases of lung, colon, renal and breast cancer and of malignant melanoma) leading to a correct rate of 96% (sensitivity: 96%, specificity: 100%).
Treatment for patients newly diagnosed with glioblastoma varies based on the size and location of the tumor, but historically it’s been comprised of surgery, radiation and chemotherapy. The new drug trial happening at UAB is focused on a different type of therapy, Drug Resistant Immunotherapy (DRI)
The University of Alabama at Birmingham (UAB) continues to evolve as a worldwide leader in biomedicine, research and innovation. A Birmingham-based biopharmaceutical company has now announced the initiation of a Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma. This trial is being conducted at UAB and is now active and open for enrollment.
In recent years, Johns Hopkins and several other academic medical centers around the world have been able to safely access tumors through brainstem safe entry zones. Yet, the benefits of aggressive resection have been unclear. Our study aimed to clarify the OS benefit among these patients.”
In research published in Science Advances, Xavier Intes, a professor of biomedical engineering at Rensselaer, joined a multidisciplinary team from Northeastern University and the Icahn School of Medicine at Mount Sinai to demonstrate a methodology that combines the bioprinting and imaging of glioblastoma cells in a cost-effective way that more closely models what happens inside the human body.
Venom, whether in snakes, scorpions or Gila monsters, are very complex chemicals. And in more than one instance, research into them has led to effective drugs.
Researchers with City of Hope have developed a chimeric antigen receptor (CAR) T cell therapy leveraging chlorotoxin (CLTX), a component of scorpion venom. In preclinical research published in Science Translational Medicine, they demonstrated that the therapeutics directed T cells to target brain tumor cells.
Researchers who discovered that an engineered cold sore virus could help destroy brain tumors from the inside out have determined a one-two punch might be the key to finish them off. This virotherapy could make a class of investigational cancer drugs more effective, according to investigators at The University of Texas Health Science Center at Houston (UTHealth).
University Hospitals is a part of a groundbreaking clinical study. It’s one of four places in the world that is working to slow the growth of malignant brain tumors, by injecting another disease in it.
MRI could help identify which patients with aggressive brain tumors might benefit from liquid biopsy, the blood test that pinpoints cancer DNA in a patient’s bloodstream. New research published today in Neuro-Oncology Advances shows that adding imaging to the mix when trying to diagnose and biopsy for glioblastoma (GBM) can help physicians determine which patients are good candidates for a liquid biopsy, as well as those who aren’t.
A new study will test a combined cancer vaccine which triggers immune responses against molecules that are expressed by GBM tumors. As it is a combined vaccine, it will target two molecules (TRP2 and WT1) which both play a significant role in GBM and are expressed in many GBM cells. It is expected that this study will provide a basis on which to move this new approach into the clinical setting.
GammaTile Therapy, marketed by GT Medical Technologies, became available to patients in January 2019 and is being used in top cancer treatment centers across the United States. It was initially approved for the treatment of recurrent brain tumors, including glioblastomas, gliomas, meningiomas, and brain metastases. The FDA expanded clearance of the technology in January to include treatment of newly diagnosed malignant brain tumors.
Scientists at the University of Pennsylvania have demonstrated that targeting a mechanism in a subset of stromal cells known as endothelial cells—which line the inside of blood vessels—might help overcome drug resistance in glioblastoma.
Yale researchers have found a way to weaponize structures from the Ebola virus in the fight against glioblastomas — ruthless brain tumors that are notoriously difficult to subdue.
Doctor has pushed the boundaries of innovation in her quest to increase the survival rates of individuals with brain tumors, especially glioblastomas. The esteemed physician-scientist has taken a truly comprehensive approach to battling this rare disease, which has a five year survival rate of only 10 percent and claimed the lives of U.S. Sens. Ted Kennedy and John McCain.
Researchers at the University of Virginia School of Medicine have determined that a rare childhood cancer, medulloblastoma, forms an unexpectedly intricate network to drive its growth. Some tumor cells actually turn into another type of cell altogether. The discovery raises the exciting possibility that doctors may be able to intervene to stop the disease – and possibly other cancers as well.
Radiation oncologists at the University of Louisville have for the first time in the U.S. treated a metastatic brain tumor with intraoperative radiation therapy supplied with the use of iCAD’s Xoft Axxent Electronic Brachytherapy System.
Glioblastomas are relentless, hard-to-treat, and often lethal brain tumors. Yale scientists have enlisted a most unlikely ally in efforts to treat this form of cancer — elements of the Ebola virus. The irony is that one of the world’s deadliest viruses may be useful in treating one of the deadliest of brain cancers,”
A study published in JAMA Oncology confirmed an association between maximal resection of contrast-enhanced tumor and overall survival (OS) in patients with glioblastoma across all subgroups.
Additionally, the researchers found that maximal resection of non-contrast-enhanced tumor was associated with longer OS in younger patients, regardless of isocitrate dehydrogenase (IDH) status, and among patients with IDH-wild-type glioblastoma regardless of the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase.
A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers. Yet a Mayo Clinic team and their collaborators took that counterintuitive approach and discovered that while it created resistance to chemotherapy, it also made tumors sensitive to immunotherapy.
Survival may more than double for adults with glioblastoma, the most common and deadly type of brain tumor, if neurosurgeons remove the surrounding tissue as aggressively as they remove the cancerous core of the tumor.
This discovery, reported in a retrospective study headed by researchers at UC San Francisco, is welcome news for those in the glioblastoma community, which celebrated its last breakthrough in 2005 with the introduction of the chemotherapy drug temozolomide.
Sam underwent DNA and RNA genomic sequencing at Mott to confirm which mutation was driving his cancer and help match him with an unconventional treatment to target that specific mutation. The sequencing results convinced doctors to treat the teen with a drug called everolimus – typically used to prevent rejection of organ transplants and in the treatment of renal cell cancer, not brain tumors.
Research in cell cultures and animal models suggests that scientists may be able to use a modified poliovirus to mount an immune response against brain tumor cells. Scientists know that the poliovirus is the pathogen that causes poliomyelitis, a disease that affects the central nervous system, potentially causing disability and, in the most severe cases, death.
Chinese researchers have developed robotic worms that can move through blood vessels to reach patients’ brains and directly destroy the tumors, avoiding the serious side effects of conventional treatments. According to an article in the South China Morning Post, researchers were able to create robotic worms that can travel through blood vessels to reach patients’ brains and target tumors directly.
Research in cell cultures and animal models suggests that scientists may be able to use a modified poliovirus to mount an immune response against brain tumor cells.
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.
Scientists at Baylor College of Medicine have found new evidence that glioma, a lethal form of brain cancer, alters the activity of neighboring neurons, accelerating a vicious cycle that drives tumor-associated epilepsy and tumor progression. Their findings, published in Nature, showed that several variants of the PIK3CA gene drive tumor progression and that two variants in particular alter the expression of genes involved in synapses—junctions through which neurons communicate.
Researchers are at work to find effective treatments to help young patients with brain tumors. Hundreds of brain organoids have been developed in the laboratories of the University of Trento to understand the genetic mechanisms responsible for these hard-to-treat diseases.
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.
The FDA has given the green light to an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to patients newly diagnosed with malignant brain tumors. About the size of a postage stamp, the bioresorbable GammaTile is designed to be placed within the brain after excision surgery, to deliver local doses of radiation at the site of any remaining cancer cells.
The Israeli-developed device, called the Optune helmet, said to prevent tumor growth using electric pulses, while causing minimal damage to healthy tissue. This FDA-approved treatment comes in the form of a device that delivers Tumor Treating Fields (TTFields) for glioblastoma (GBM), an aggressive form of brain cancer.
The first successful GammaTile procedure in North Carolina was recently performed at Vidant Medical Center.
Officials announced Thursday that the procedure, done along with East Carolina University's Brody School of Medicine, delays aggressive tumor regrowth for patients with brain tumors.
Cancer remains to be one of the medical research community's huge focuses and challenges, and scientists in Houston are continuing to innovate new treatments and technologies to make an impact on cancer and its ripple effect. Three research projects coming out of Houston institutions are providing solutions in the fight against cancer — from ways to monitor treatment to eliminating cancer-causing chemicals in the first place.
For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven to be an effective alternative to invasive surgery, thus potentially improving patient quality of life while significantly reducing the cost of care.
In a study led by Michigan Medicine, researchers combined laser imaging with artificial intelligence to help predict brain tumor diagnosis within minutes.
A new publication in Nature Medicine highlights how the NIO Imaging System from Invenio Imaging allows surgeons to get a real-time image of a piece of tissue from surgery and use artificial intelligence to get a rough diagnosis of the tissue’s composition.
A new study shows that children with medulloblastoma who were treated with radiotherapy had better intellectual outcomes when the radiation was delivered as proton beam therapy compared to traditional photon radiotherapy.
Researchers at NYU Grossman School of Medicine and the University of Michigan are proposing a new approach that may lead to more accurate brain tumor diagnoses by combining advanced optical imaging and artificial intelligence.
Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a "suicide gene" to pediatric brain tumor cells implanted in the brains of mice. The poly(beta-amino ester) nanoparticles, known as PBAEs, were part of a treatment that also used a drug to kill the cells and prolong the test animals' survival.
An optical imaging technique paired with an AI algorithm was able to analyze a tissue sample in less than 150 seconds, demonstrating how machine-learning can make a huge impact in the operating room. The AI was also able to detect some details conventional practices could miss. The new research comes as AI has recently proven to outperform humans in diagnosing breast and lung cancer.
In a paper published Monday in the journal Nature Medicine, researchers described an imaging technique called stimulated Raman histology, or SRH, that reveals tumor infiltration in human tissue by collecting scattered laser light to illuminate features not typically visible in standard histologic images.
Ground-breaking research by the University of Birmingham has discovered a new technique to assess the aggressiveness of childhood brain tumors. The study is the first of its kind and will allow clinicians to give more personalized treatments for childhood brain cancers, which currently account for one third of all childhood cancer deaths in the UK.
Glioblastoma is one of the most common and aggressive forms of brain cancer, and it is particularly difficult to treat. Now, researchers from the University of Pennsylvania School of Medicine have come up with a new approach to treatment for the disease, by growing organoids based on a patient’s own tumor to find the most effective treatments.
Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.
Using an ensemble of type-II fuzzy inference system and adaptive neuro-fuzzy inference system, a novel classifying technique has been developed to classify the detected tumor incorporating the extracted features.
Immune checkpoint inhibitors are important medications that boost the immune system's response against certain cancers; however, they tend to be ineffective against glioblastoma, the most deadly primary brain tumor in adults. New research in mice led by investigators at Massachusetts General Hospital (MGH) and the University of Florida reveals a promising strategy that makes glioblastoma susceptible to these medications.
A GPS map to guide neural navigation devices developed by a Case Western Reserve University cancer researcher has shown 90% accuracy in pinpointing brain tumors and will soon be tested in real time with patients at Cleveland Clinic under a three-year, $600,000 V Foundation grant.
While all treatments help improve outcomes, immunotherapy is potentially a “game changer,” says Donald O’Rourke, director of the GBM Translational Center of Excellence at the Abramson Cancer Center.
Northwestern Medicine scientists are using an implantable ultrasound technology to help deliver treatment for glioblastoma to the brain. The researchers detailed how they used the ultrasound to open the blood-brain barrier in mice.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
Neurosurgeons in Wisconsin employ some new technology to try to better remove a complex brain tumor. Under normal white light used while operating, neurosurgeons could only see portions of the tumor. But thanks to a new dye and filter system, they can see more.
According to various recent articles and reports tracking the new trends in immunotherapy for pediatric brain tumors, recent advances in cancer immunotherapy have improved outcomes for several human cancers, and in some cases have produced dramatic responses in patients.
A common virus that is harmless to most individuals may produce an important biomarker in determining the prognosis of brain cancer patients, according to a recent study published by a student researcher at the University of Cincinnati.
Researchers at Johns Hopkins University are studying a new experimental treatment for dogs with brain cancer. They hope their research will lead to treatments for people.
A new engineering solution may help deliver tumor killing drugs directly to the brain tumor without the toxic body effects of systemic chemotherapy. The new study published in the journal Nature Scientific Reports reports on the use of coaxial electrospinning, an industrial fabrication technology, in the production of membranes that incorporate drugs to treat glioblastoma multiforme (GBM), an aggressive cancer of the brain.
While tumors are known to compromise the integrity of the blood brain barrier—a specialized vessel wall evolved to keep the brain "safe"—the makeup of the barrier is inconsistent, which prevents drugs from being uniformly distributed throughout the tumor. Unfortunately, increasing dosages to help improve drug delivery is not possible due to the adverse effects caused by drug interactions with healthy tissue, and drug penetration to the tumor core remains limited.
By combining focused ultrasound methods with different nanoparticle formulations, Researchers have investigated two strategies for improving drug penetration into brain tumors.
Medication prescribed for a certain type of epilepsy may offer a new method for treating malignant infantile brain tumors. A specific mTOR inhibitor has the ability to cross the blood-brain barrier to both reach and attack the tumor at source.
Radiotherapy is essential for treating pediatric brain tumors, but the treatment comes with the risk of cognitive impairment. Researchers at Baylor College of Medicine, Texas Children’s Hospital and the Hospital for Sick Children (SickKids) in Toronto examined children treated with two different kinds of radiotherapy—proton radiotherapy and photon radiotherapy—and found those treated with proton radiotherapy had less intellectual decline.
Researchers from the University of São Paulo (USP) in Brazil have developed a strategy for treating the most aggressive type of brain cancer in adults that combines a photoactive molecule and a chemotherapeutic agent—both encapsulated in protein-lipid nanoparticles.
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.
The researchers showed that combining the two drugs – panobinostat and marizomib – was more effective than either drug by itself in killing DMG patient cells grown in the laboratory and in animal models. Their studies also uncovered a previously unrecognized vulnerability in the cancer cells that scientists may be able to exploit to develop new strategies against the cancer and related diseases
The researchers observed an increase in the formation of new neurons in an area that is important to the memory (the hippocampus) during the period in which they received lithium, but their maturity into full nerve cells only occurred once the lithium treatment was discontinued.
The human brain has some remarkable capabilities - including the ability to block cancer drugs from effectively reaching cancer cells in the brain. The greatest obstacle when it comes to treating cancer that has spread to the brain is the blood-brain barrier, the brain's natural defense mechanism that is a collection of blood vessels that can filter out what goes in and out of the brain.
The blood test measures the amount of cell-free DNA, or cfDNA, in the bloodstream, according to Penn Medicine News. Cancer cells and other cells shed cfDNA into the bloodstream. The researchers studied patients with glioblastoma, the most common and deadliest brain tumor, and found that those with higher bloodstream concentrations of cfDNA had a shorter "progression-free survival" than patients with less cfDNA.
A local woman who received a breakthrough brain cancer treatment is saying thank you to the team that helped save her life.
The team at Mayfield Brain & Spine is among the first in the nation to use a new kind of targeted therapy to treat recurrent brain tumors. It is called GammaTile.
Chemical analysis of blood samples, combined with an artificial intelligence program, could speed up the diagnosis of brain tumours, according to research presented at the 2019 NCRI Cancer Conference. Researchers say their test, which works by detecting chemical clues shed by brain tumours into the blood, could help improve brain tumour survival by making diagnosis quicker and more efficient.
Glioblastoma (GBM) is the type of aggressive brain cancer that took the life of Arizona Senator John McCain in 2018. A notoriously difficult cancer to treat, there have been several high-profile drug failures recently. There’s new hope, however. Researchers at Sweden’s Karolinska Institutet identified 10 potential drug targets for glioblastoma and published the results in the journal Cell Reports.
There is amazing new technology that’s helping surgeons perform the most delicate of all operations.
An adhesive hydrogel that reveals and kills cancer cells could mean the end of debilitating radiation, chemotherapy and surgery for children with brain cancer, a lethal disease that impacts thousands of pediatric patients each year.
Researchers have recently found a compound that can eradicate drug-resistant glioblastoma-initiating cells (GICs). This compound, could potentially be used to eradicate refractory tumors with minimal toxicity.
The combination of advanced imaging and artificial intelligence (AI) could make a brain tumor blood test leading to earlier diagnoses – and perhaps better prognoses, according to new research. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy, coupled with machine learning, could differentiate cancer patients and controls with better than 90% sensitivity and specificity.
A new study describes the use of an orally ingested agent called 5-aminolevulinic acid (5-ALA) to confirm the diagnosis of the aggressive brain tumor called glioma. This agent causes a naturally occurring fluorescent molecule called protoporphyrin IX (PpIX) to accumulate inside the tumor cells selectively.
A chemical that has improved surgeries for brain cancer by making tumor cells fluorescent may also help doctors safely diagnose the disease and monitor its response to treatment, according to a new study led by investigators at Massachusetts General Hospital
A new blood test that can detect brain cancer has been developed in the United Kingdom. It’s cutting edge technology uses artificial intelligence and has a high accuracy rate. This new blood test sounds very promising. Now what the researchers did was to use an infrared light technique to produce what’s called a biochemical ‘fingerprint’.
A new blood test that can detect brain cancer has been developed in the United Kingdom. It’s cutting edge technology uses artificial intelligence and has a high accuracy rate. This new blood test sounds very promising. Now what the researchers did was to
Researchers for the University of Strathclyde have developed the test, which uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer.
Researchers at Tufts University have just developed a way to create an environment that closely mimics that of the brain and were able to grow pediatric and adult tumors within it. The microenvironment allows for non-invasive imaging of the tumors and for easy manipulation of the cells growing within.
Tiny bubbles in the brain might offer some respite for some. An experiment using those bubbles to help treatment drugs get to places normally out of reach. The technique could give patients with glioblastomas far longer lives. It could also offer a way to treat other devastating brain diseases such as Alzheimer’s and Parkinson’s.
Ribociclib, a drug that was recently FDA-approved for breast cancer, is part of a new class of drugs that target cell division thereby suppressing cancer progression.
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Versions of an antibiotic drug called DON first isolated from soil bacteria more than 60 years ago have shown promising signs of extending survival in mice models of especially lethal pediatric brain tumors marked by the high expression of a cancer-causing gene known as the MYC oncogene.
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers
A research team from the University of Georgia’s Regenerative Bioscience Center has found that a compound molecule used for drug delivery of insulin could be used to treat glioblastoma, an aggressive, usually fatal form of brain cancer.
Researchers found a positive and negative correlation with a host of blood molecules, including the ratio of neutrophils to lymphocytes, platelets to lymphocytes and monocytes to lymphocytes. Some of these were able to predict a good or bad outcome, while others were limited to only childhood tumors.
A research team from the University of Georgia's Regenerative Bioscience Center has found that a compound molecule used for drug delivery of insulin could be used to treat glioblastoma, an aggressive, usually fatal form of brain cancer.
Researchers have developed a new model to optimize radiation therapy and significantly increase the number of tumor cells killed during treatment. The new mathematical model, outlined in a recent study can use information about where the majority of the cells in a tumor are located allowing for radiation treatment to be administered to the densest area.
A new therapy for treating glioma, an aggressive brain tumor, was shown to be safe in patients and cleared other important hurdles, according to a phase 1 trial recently published in Science Translational Medicine. The therapy induces production of a cancer-fighting cytokine in the brain, which could be less toxic and more effective than delivering the cytokine itself intravenously,
In their initial report, the researchers focused on diffuse intrinsic pontine gliomas, or DIPG, an inoperable brainstem tumor found in children. The team concluded that a specific class of drugs have the potential to kill mutant tumor cells.
For the first time, scientists have shown that a new type of immunotherapy can reach and treat brain cancer from the bloodstream in mice. The nano-immunotherapy stopped brain tumor cells multiplying and increased survival. Scientists who devised an immunotherapy that can cross the blood-brain barrier in mice hope that the findings may one day translate to humans.
A team of students from Ohio has created a new drug that has the potential to treat one of the deadliest forms of brain cancer. The breakthrough is expected to end the need for surgeries that are known to have side effects and death risk. Pharmacy students developed the oral compound RK15. They said the drug mainly targets the aggressive brain cancer glioblastoma and is very reactive to killing the harmful cells
A new study gives insight into how immunotherapies, treatments that help the body's immune system fight cancer, might one day be delivered directly to the brain in order to treat brain tumors. The study demonstrated that a new type of nano-immunotherapy traversed the blood-brain barrier in laboratory mice, inducing a local immune response in brain tissue surrounding the tumors. The tumor cells stopped multiplying, and survival rates increased.
Researchers led by Texas A&M University’s College of Veterinary Medicine & Biomedical Sciences have identified a new pathway they believe may help suppress the development of glioblastoma tumors. The pathway in question involves the AH receptor, which controls the expression of a diverse group of genes.
New research could be the first step towards developing a blood test to diagnose glioblastomas. A team from Professor Georgios Giamas' lab at the University of Sussex has identified novel biomarkers within bodily fluids, which signal the presence of the tumour. Cancer biomarkers are molecules that are either exclusively found or over-expressed in cancer cells, as compared to 'normal', healthy cells. Biomarkers can be considered as biological signatures for a disease, as they indicate the presence of cancer in the body.
Researchers at Tel Aviv University found that immunotherapy with vaccines based on synthetic DNA may be an effective means of preventing brain metastases. A new Tel Aviv University study has found that a known adjuvant – an ingredient used in vaccines that enhances the immune response – that contains synthetic DNA, may be an effective in preventing brain metastases in patients whose primary tumors have been excised.
Report analyses the Brain Tumor Diagnosis And Therapeutics market By Type, By Applicatio, assesses the market By Region (Europe, Asia Pacific, North America, Rest of the world) and By Country (United Kingdom, Germany, U.S., Canada, Mexico, Japan, India, France, China, Australia), assesses the market for the historical period of 2014-2018 and the forecast period of 2019-2024.
A new drug, known as IP1867B, could be used for future treatments of brain tumors. The research team showed that IP1867B worked with existing cancer treatments boosting their effectiveness and, in some cases, restored sensitivity to some treatments.
Forrest General became the first hospital in Mississippi to use Gleolan™ (aminolevulinic acid HCl) for enhanced visualization of high-grade gliomas (including glioblastomas), or tumors occurring in the glial cells of the brain. This solution causes tumor cells to glow red under blue light allowing the neurosurgeon to remove as much of the tumor as possible without affecting healthy brain cells.
An international team led by researchers has discovered the energy production mechanism of cancerous cells that drives the growth of the nucleolus and causes tumors to rapidly multiply. The findings could lead to the development of new cancer treatments that would stop tumor growth by cutting the energy supply to the nucleolus.
Massachusetts General Hospital (MGH) investigators have created a new method that could make immune therapy more effective again brain tumors and expand its use against other types of solid tumors.
The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered class of targeted therapy that undermines cancer cell division and could form the backbone of a new drug cocktail for patients with malignant brain tumors like glioblastoma.
Investigators at St. Jude Children's Research Hospital and Massachusetts General Hospital, alongside others, have revealed the cells of origin for specific subtypes of medulloblastoma, the most common malignant pediatric brain tumor. The work also has implications for how medulloblastoma is classified, which may eventually shape clinical care.
In immunotherapy for cancer, the buzziest area of research is combinations: one checkpoint drug with another, say, or a checkpoint drug with chemotherapy. The latest brainstorm is an acronym lover’s dream team: CAR-Ts and BiTEs.
A combination of chemotherapy drugs during brain cancer surgery using a biodegradable paste, leads to long-term survival, researchers at the University of Nottingham have discovered. In a new study published in Clinical Cancer Research, scientists found a significant survival benefit in rat models with brain tumors when a combination of two chemotherapy drugs, (etoposide and temozolomide), were delivered using a biodegradable polymer called PLGA/PEG.
"Tumor treating fields are a technology that creates a low level electrical field and it disrupts cells that are trying to divide," said David Peereboom, M.D., of Cleveland Clinic. "And since it is cancer cells that are actually the ones dividing, those get killed preferentially."
Researchers at the University of Nottingham have discovered that repurposing a heart drug could significantly increase the survival rate for children with ependymoma - a type of brain tumour.
Karyopharm Therapeutics’ new product, Xpovio to treat multiple myeloma, is the first entry in a class known as Selective Inhibitor of Nuclear Export (SINE) drugs, and the FDA approval the company secured for the product earlier this month is quite limited. But one research group sees potential for Xpovio in another cancer type: glioblastoma.
Toronto's St. Michael's Hospital and The Hospital for Sick Children (SickKids) led the new research which suggests the protein ID1 is crucial to tumor initiation and development and also impacts the response of the disease to chemotherapy.
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA's platform immunotherapy targeting cancer stem cells.
After surgery or biopsy, all patients received radiotherapy & chemotherapy with the chemotherapeutic agent temozolomide; then received temozolomide again and 2/3 of them (466) were additionally treated with TTF. The study lasted 24 months, but there was an interim analysis for the outcome of mortality after 18 months. Due to positive results in this analysis, participants in the control group were then free to switch to the TTF study arm.
Research is currently pursuing several highly promising approaches in the fight against cancers that give rise to metastases in the brain. A high-level international symposium is currently taking place to discuss new approaches to prevention and treatment. "Our aim must be to prevent brain metastasis from occurring in the first place,". However, new forms of treatment are now also available for patients who already have secondary tumors in the brain.
A team of Turkish researchers developed a nano-technological drug delivery system that can overcome the natural defense mechanism that prevents drugs from reaching the tumor in brain cancer patients, without harming any healthy tissues, unlike the chemotherapy method that is generally used in treatment of the disease.
It can be hard for surgeons to tell the difference between glioblastomas and brain tissue. A new drug is helping by turning the tumor bright pink.
Glioblastomas attract "turncoats." These are macrophages, a type of immune cell, which promote tumor progression and mask tumors from the immune system's scrutiny. To better understand the cells that brain tumors recruit, scientists led by Dolores Hambardzumyan, Ph.D., developed advanced imaging techniques to visualize macrophages found in the brain tumors of living mice.
Data reinforce the safety profile of GammaTile Therapy, a surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with recurrent intracranial neoplasms (brain tumors).
Dr. Ahluwalia is helping lead a clinical trial of a new glioblastoma treatment called SurVaxM. It’s an immunotherapy for brain cancer that works by stimulating a person’s own body to kill tumor cells that contain survivin, a protein that helps those cancer cells resist traditional treatments.
Using a new approach that combines data from human tumors grown in mice with data from The Cancer Genome Atlas, a team led by University of Michigan Rogel Cancer Center researchers has uncovered several previously unknown biomarkers for glioblastoma, the most common malignant brain tumor.
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking it, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Cell.
The fluorescent tumor technology allows neurosurgeons to identify and remove as much of the tumor as they can while leaving healthy brain tissue intact. Doctors say it's a game-changer.
A Kuwaiti medical team succeeded in eradicating a brain tumor using the surgical technique (Curve), the latest in specialized treatment.
For brain tumor patients who are resistant to chemotherapy, radiation and existing treatment options, surgery are central to survival.
7D Surgical, one of the leaders in advanced optical technologies and vision-based surgery algorithms, flagship product, the MvIGS technology has the power to obtain hundreds of thousands of virtual fiducials leveraging the patient’s anatomy which allows for immediate cranial registration in just about any surgical position.
The blood-brain barrier normally blocks many types of drugs from entering the central nervous system, making it hard to treat brain disorders. Scientists hope to solve that problem with the help of an unlikely ally: the jawless sea lamprey. And they have promising early evidence that a molecule derived from the creature could be used to ferry drugs directly to previously difficult-to-access diseased sites in the brain.
The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to shrink and his cognitive symptoms eased. Soon the tumor had all but disappeared. Today he’s still on the drug but back at school and doing well.
A new Northwestern Medicine study finds that a combination of two mutations cause a form of pediatric brain tumors to become more deadly, according to findings published in Nature Communications. An experimental drug targeting one mutation prolonged survival in models of diffuse intrinsic pontine glioma (DIPG), but questions remain about the drug’s efficacy,
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
Doctors at Swedish Hospital in Seattle say they’re on the verge of a breakthrough they hope will add years of survival for brain cancer patients. KIRO 7 went to the lab this week to see the cutting edge research.